It’s official. Biomet, Inc. is going public to reduce company debt.
Biomet Going Public to Reduce Debt

The company announced on March 7, 2014 that its parent company, LVB Acquisition, Inc., has filed a registration statement with the Securities and Exchange Commission (SEC) for a proposed initial public offering of its common stock. In connection with the offering, LVB Acquisition intends to change its name to Biomet Group, Inc.
The number of shares to be offered and the price range for the proposed offering have not yet been determined. BofA Merrill Lynch, Goldman, Sachs & Co., J.P. Morgan, Citigroup, Wells Fargo Securities, Barclays and Morgan Stanley are acting as the joint book-running managers for the offering.
Previous and accurate news reports stated that according to unnamed “people, ” the public offering that could raise around $1 billion.
The preliminary prospectus was not yet available.
This will bring to full circle the company being a public corporation again being taken private for $11.3 billion in 2007 by four Wall Street buyout firms. The buyout came after company founder, Dane Miller, Ph.D. was removed as the company CEO. He returned with the bankers to retake the public company by buying out the public shareholders. According to securities filings, $5.9 billion of debt still remains on the company’s balance sheet.
That debt is in stark contrast to Biomet competitors sitting on huge piles of cash.
Biomet expects to use the net proceeds of the offering primarily to reduce outstanding indebtedness.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.